Nicholas Short, MD, Discusses Triplet Combination for FLT3-mutated AML
By Cecilia Brown, Nicholas Short, MD - Last Updated: February 1, 2023Nicholas Short, MD, of the MD Anderson Cancer Center, discusses updated results from a phase I/II study of azacitidine, venetoclax, and gilteritinib in patients with FLT3-mutated acute myeloid leukemia. Dr. Short and colleagues presented the results of the study at the 2022 American Society of Hematology Annual Meeting.
Advertisement
Post Tags:ASH22
Advertisement
Related Posts
New data on immune thrombocytopenia were most prominent but Meeting coverage ranged over several forms of the disease.
Andrew Kuykendall, MD, presented on the status of myelofibrosis treatment in the era of 4 approved JAK inhibitors.
The CARTITUDE-4, KarMMa-3, and DREAMM-7 trials are paving the way for immunotherapy in multiple myeloma.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
The several considerations involved with these agent classes make discussions with patients of treatment decisions crucial.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.